Mark Enyedy, Director at Fate Therapeutics, holds 0.00 shares in Fate Therapeutics (Ticker: FATE), holds 6.90K shares in BioMarin Pharmaceutical (Ticker: BMRN), holds 0.00 shares in ImmunoGen (Ticker: IMGN). Most recently, Mark Enyedy ― shares of Fate Therapeutics on ― for an estimated value of ―.
Mark Enyedy latest transaction was an Uninformative Buy of ―.
What was Mark Enyedy's most profitable transaction?
Mark Enyedy’s most profitable transaction was an Informative Buy of IMGN stock on November 9, 2016. The return on the trade was 187.10%.
What is Mark Enyedy's role in Fate Therapeutics?
Mark Enyedy's role in Fate Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.